Assessment of early paraprotein response to vincristine-doxorubicin- dexamethasone chemotherapy may help guide therapy in multiple myeloma

D. M. Ross, L. B. To, Noemi Horvath

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Vincristine, doxorubicin and dexamethasone (VAD) are commonly used as the initial chemotherapy in myeloma patients prior to high-dose therapy and autologous stem cell transplantation. We reviewed monoclonal protein responses and survival of 62 patients treated in this way. Among patients with IgG paraprotein, achievement of at least 50% reduction in paraprotein after the first cycle of VAD correlated with significantly better event-free survival at 3 years, compared with those having less than 50% response. We postulate that early paraprotein response may be used to identify high risk patients.

Original languageEnglish
Pages (from-to)576-578
Number of pages3
JournalInternal Medicine Journal
Volume34
Issue number9-10
DOIs
Publication statusPublished - 1 Sep 2004
Externally publishedYes

Keywords

  • Autologous transplantation
  • Multiple myeloma
  • Paraprotein
  • Prognostic factors

Fingerprint Dive into the research topics of 'Assessment of early paraprotein response to vincristine-doxorubicin- dexamethasone chemotherapy may help guide therapy in multiple myeloma'. Together they form a unique fingerprint.

  • Cite this